Your Feed

Filter by
See content from
Back to the latest
Avatar
GratefulGrit
Multiple Myeloma Discussion • September 28, 2025
Medicare Plan G Check-In for 2026?
AI-generated title
I have traditional Medicare with AARP Medicare Supplement Plan G and Wellcare for a drug plan. So far, this combination has served me well. For 2026, besides rates increases, do I need to make any adjustments/changes?
Thumbnail for Isatuximab’s On-Body Delivery System (Sub-q)- IRAKLIA Trial | Claudio Cerchione, MD | #IMS2025
Playlist: IMS 2025

Isatuximab’s On-Body Delivery System (Sub-q)- IRAKLIA Trial | Claudio Cerchione, MD | #IMS2025

Video details & playlist
Thumbnail for The CELMoD, Mezigdomide, Shows Dramatic Results in Relapsed Myeloma | Paul Richardson, MD | #IMS25
Playlist: IMS 2025

The CELMoD, Mezigdomide, Shows Dramatic Results in Relapsed Myeloma | Paul Richardson, MD | #IMS25

Video details & playlist
Avatar
Claudia
Multiple Myeloma Discussion • September 26, 2025
Preparing for SCT at OHSU: Questions & Tips?
AI-generated title
We leave on Thursday to go to OHSU for Brian’s SCT. Needless to say, there is excitement along with a good dose of appreciation. Has anyone had their transplant at OHSU? Any insights? Has anyone stayed at the Rood Family Pavilian? Do they have laundry facilities? Anything you wish you had brought, left home? We will be in Portland for 6-8 weeks; it feels uncomfortable to leave our home for that long. I’d love to know what might help during this process. ~Claudia
Thumbnail for Shared Decision Making in Myeloma- Understanding Treatment Goals Together| Lisa Leypoldt, MD #IMS25
Playlist: IMS 2025

Shared Decision Making in Myeloma- Understanding Treatment Goals Together| Lisa Leypoldt, MD #IMS25

Video details & playlist
Thumbnail for Promising Myeloma Advances: Belantamab Combos Show Favorable Outcomes  Paul Richardson, MD | #IMS25
Playlist: IMS 2025

Promising Myeloma Advances: Belantamab Combos Show Favorable Outcomes Paul Richardson, MD | #IMS25

Video details & playlist
Avatar
Navysafetywoman
Multiple Myeloma Discussion • September 25, 2025
IgG Infusions: Why Are They Needed?
AI-generated title
Can some explain to me in plain language of why I have to get IGG INFUSION? My oncologist said that my numbers were low and not in range but what does that mean? What would happen if it's not in range?
Avatar
caraofeve
Multiple Myeloma Discussion • September 25, 2025
Considering No ASCT - Your Stories?
AI-generated title
Hello everyone and thank you in advance for reading and any input you can provide? Has anyone had any experience or information related to after induction therapy opting not to proceed with a ASCT although eligible and it was recommended? I understand the standard of care and process entailed therein however have not heard much detailed information or testimony as to why anyone opted not to proceed with ASCT (what factors lead them to were that decision). What was their outcome? I am trying to balance both side of the coin. I am scheduled for my ASCT consult on October 15th at the Mayo Clinic. Any advice or information is greatly appreciated. I want to ask all the right questions and explore all options and avenues of care. I am 55, was diagnosed with Multiple Myeloma on July 9, 2025. To my disappointment I learned (in preparation for an evaluation with a MM specialist at Mayo) my hematologist/oncologist identified my diagnosis date as 5/22 and test results support the diagnosis on this date. However I was not verbally informed until 7/9, after a PET Scan on 6/17 and a bone marrow biopsy on 6/19, that I have Multiple Myeloma and started induction therapy on 7/16 with the 4 drug regimen D-VRd. I am a good patient and believe in medicine and my drs and follow instruction/advice to the tee. It is true that anyone with Multiple Myeloma should have a MM specialist on their care team. I will continue to receive my induction and the hemotologist/oncologist at MDAnderson however the MM specialist at Mayo will coordinate and headup my care. I was informed by my Myeloma specialist that I have Kappa Light Chain MM. I would have been high risk based on chromosome t(4:14) but that alone has been downgraded as of June 2025 by itself. I am Stage 2 . My kappa light chain was 3646 on 5/23/25 but dropped to 14 as of 8/30/25. I was experiencing side effects of waking up with crusty eye in the morning and nueropathy. The MM specialist believed stopping the bortizemib would be beneficial as it has done what it needed to do and continued use could have more adverse effects therefore I completed 2 cycles of the D-VRd and started the 3rd cycle with only 3 medicines; Darzalex Faspro (every 3 weeks), Lenalidomide (21 day on and 7 off) and dexamethasone (40 mg a week-all at once). Both the crusty eye and nueropathy have reduced significantly since I stopped the bortizemib. The MDAnderson team advised me they do not agree with the MM specialist's assessment but they would make the adjustment and let's see what happens ... I overall feel good. I feel much better now that I have the MM specialist on my team. He has answered all my questions and understand my disease in a way the others did not. He has answered all my questions and has been able to explain and answer ever question I had where they others could not. I am sleep challenged and I gained 5 lbs. but otherwise I am ok. I am that can do person. However I realize I need to be extremely proactive and informed in this case with my Myeloma. I want to be the co-pilot versus a back seat driver and plan to educate myself and utilize the amazing resources and network provide by the HealthTree Foundation. Denise
Thumbnail for Functional High-Risk Myeloma:CAR-T Optimizes Outcomes at Relapse | Rahul Banerjee, MD | #IMS2025
Playlist: IMS 2025

Functional High-Risk Myeloma:CAR-T Optimizes Outcomes at Relapse | Rahul Banerjee, MD | #IMS2025

Video details & playlist
Thumbnail for Comparing Imaging Techniques for Myeloma Response Assessment | Marco Talarico, MD, PhD(c) | #IMS2025
Playlist: IMS 2025

Comparing Imaging Techniques for Myeloma Response Assessment | Marco Talarico, MD, PhD(c) | #IMS2025

Video details & playlist
Thumbnail for Choosing Between CAR-T and Bispecific Antibodies: Patient Perspectives | Valeria Escobedo | #IMS2025
Playlist: IMS 2025

Choosing Between CAR-T and Bispecific Antibodies: Patient Perspectives | Valeria Escobedo | #IMS2025

Video details & playlist
Thumbnail for Patient Reported Outcomes (PROs) indicate Linvoseltamab Improves QOL | Joshua Richter, MD | #IMS25
Playlist: IMS 2025

Patient Reported Outcomes (PROs) indicate Linvoseltamab Improves QOL | Joshua Richter, MD | #IMS25

Video details & playlist
Thumbnail for High-Risk Myeloma -CONCEPT Trial-Isatuximab, Kyprolis, Revlmid, Dex. |Lisa Leypoldt, MD #ims25
Playlist: IMS 2025

High-Risk Myeloma -CONCEPT Trial-Isatuximab, Kyprolis, Revlmid, Dex. |Lisa Leypoldt, MD #ims25

Video details & playlist
Thumbnail for Likely Change in IMWG Myeloma Response Criteria : 24-Hour Urine & More | Rahul Banerjee, MD | #IMS25
Playlist: IMS 2025

Likely Change in IMWG Myeloma Response Criteria : 24-Hour Urine & More | Rahul Banerjee, MD | #IMS25

Video details & playlist
Avatar
caraofeve
General Discussion • September 25, 2025
Considering Not Getting an ASCT - Your Experiences?
AI-generated title
Hello everyone and thank you in advance for reading and any input you can provide? Has anyone had any experience or information related to after induction therapy opting not to proceed with a ASCT although eligible and it was recommended (not frail)? I understand the standard of care and process entailed therein however have not heard much detailed information or testimony as to why anyone opted not to proceed with ASCT (what factors were that decision was based on) and what was their outcome was? I am trying to balance both side of the coin. I am scheduled for my ASCT consult on October 15th at the Mayo Clinic. Any advice or information is greatly appreciated. I want to ask all the right questions and explore all options and avenues of care. I am 55, was diagnosed with Multiple Myeloma on July 9, 2025. To my disappointment I learned (in preparation for an evaluation with a MM specialist) my hematologist/oncologist identified my diagnosis date as 5/22 and test results support the diagnosis on this date. However I was not verbally informed until 7/9, after a PET Scan on 6/17 and a bone marrow biopsy on 6/19, that I have Multiple Myeloma and started induction therapy on 7/16 with the 4 drug regimen D-VdR. I am a good patient and believe in medicine and my drs and follow instruction/advice to the tee. I am that can do person. However I realize I need to be extremely proactive and informed in this case with my Myeloma. I want to be the co-pilot versus a back seat driver and plan to educate myself and utilize the amazing resources and network provide by the HealthTree Foundation. Denise
Thumbnail for Maintenance Therapy : Revlimid vs. Revlimid + Dara | AURIGA Update| Larry Anderson, MD, PhD | #ims25
Playlist: IMS 2025

Maintenance Therapy : Revlimid vs. Revlimid + Dara | AURIGA Update| Larry Anderson, MD, PhD | #ims25

Video details & playlist